Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00AYW
|
|||
| Drug Name |
HMS5552
|
|||
| Synonyms |
Dorzagliatin; UNII-X59W6980E8; X59W6980E8; 1191995-00-2; Sinogliatin; RO5305552; Dorzagliatin [INN]; Dorzagliatin [USAN:INN]; SCHEMBL1079619; HMUMWSORCUWQJO-QAPCUYQASA-N; HMS-5552; AKOS030527745; RO-5305552; (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5; (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R; (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide; (2S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
Hua Medicine Shanghai, China
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H27ClN4O5
|
|||
| Canonical SMILES |
CC(C)CC(C(=O)NC1=NN(C=C1)CC(CO)O)N2CC(=CC2=O)OC3=CC=CC=C3Cl
|
|||
| InChI |
1S/C22H27ClN4O5/c1-14(2)9-18(22(31)24-20-7-8-26(25-20)11-15(29)13-28)27-12-16(10-21(27)30)32-19-6-4-3-5-17(19)23/h3-8,10,14-15,18,28-29H,9,11-13H2,1-2H3,(H,24,25,31)/t15-,18+/m1/s1
|
|||
| InChIKey |
HMUMWSORCUWQJO-QAPCUYQASA-N
|
|||
| CAS Number |
CAS 1191995-00-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.